GleamWall
中文EN

BOLT Bolt Biotherapeutics, Inc.

Pharmaceutical Preparations · Nasdaq · SEC CIK 1641281 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY-51.3%
TTM net income YoY38.7%
TTM EPS YoY37.1%
Revenue 3-yr CAGR-29.4%
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin-1,098.0%
Net margin-1,034.4%
FCF margin—
EBITDA margin-1,068.0%

Returns

ROE-128.8%
ROA-52.0%
ROIC (approx.)-481.0%
Asset turnover0.05x

Leverage & solvency

Liabilities / assets75.9%
Debt / equity0.00x
Current ratio2.05x
Interest coverage—

Cash quality & payout

Operating cash flow / net income0.95x
Accruals ratio-2.7%
Payout ratio—
Capex / revenue—

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item 2026Q32026-09-302026Q22026-06-302026Q12026-03-312025Q4*2025-12-312025Q32025-09-302025Q22025-06-302025Q12025-03-312024Q4*2024-12-31
Income statement
Revenue$0$5,000$26,000$2.50M$2.17M$1.80M$1.22M$0
R&D expense$2.21M$4.72M$5.25M$4.99M$6.54M$7.50M$9.51M$11.72M
SG&A expense$2.52M$2.42M$2.80M$3.12M$3.34M$3.52M$3.83M$3.95M
Operating income-$4.73M-$7.95M-$8.03M-$7.08M-$7.70M-$9.21M-$12.12M-$16.92M
Net income-$4.42M-$7.46M-$7.67M-$6.63M-$7.14M-$8.56M-$11.04M-$15.94M
EBITDA-$4.63M-$7.75M-$7.82M-$6.83M-$7.40M-$8.91M-$11.72M-$16.49M
EPS (basic)-2.25-3.88-3.99—-3.72-4.46-5.76—
EPS (diluted)-2.25-3.88-3.99—-3.72-4.46-5.76—
Weighted avg. shares (diluted)1.97M1.92M1.92M—1.92M1.92M1.92M—
Balance sheet
Cash & equivalents$13.78M$12.86M$11.61M$11.70M$17.75M$9.60M$8.39M$7.21M
Short-term investments$1.02M$4.74M$11.28M$15.80M$14.16M$25.17M$30.45M$40.12M
Current assets$17.08M$20.56M$25.75M$30.26M$35.61M$38.34M$42.51M$50.81M
PP&E, net$341,000$408,000$1.04M$1.25M$1.50M$1.72M$2.06M$3.14M
Total assets$35.59M$40.18M$48.03M$56.75M$65.05M$75.50M$85.86M$99.63M
Current liabilities$8.31M$7.87M$7.77M$8.44M$9.97M$12.31M$13.56M$15.86M
Total liabilities$27.03M$27.70M$28.63M$30.24M$32.95M$36.66M$39.05M$42.43M
Shareholders' equity$8.56M$12.48M$19.40M$26.50M$32.10M$38.84M$46.81M$57.20M
Shares outstanding2.15M1.93M1.92M1.92M1.92M1.92M38.34M1.92M
Cash flow statement
Operating cash flow-$3.08M-$6.54M-$8.02M-$7.16M-$9.73M-$9.60M-$13.37M-$14.43M
Capital expenditure$0——$0$72,000——$0
Free cash flow-$3.08M——-$7.16M-$9.80M——-$14.43M
Investing cash flow$4.00M$7.77M$7.92M$1.07M$17.88M$10.79M$14.55M$12.23M
Financing cash flow$0$19,000$6,000$5,000$0$14,000$0$29,000
Depreciation & amortization$100,000$200,000$203,000$255,000$300,000$300,000$399,000$426,000
Stock-based compensation$506,000$552,000$545,000$1.04M$407,000$625,000$709,000$1.18M

Free plan shows the latest 8 periods; Pro shows all 27 🔒

· This company does not report gross profit in XBRL.

· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.